Great Novel Therapeutics Biotech & Medicals (ROCO:7427) EV-to-EBIT : -10.72 (As of May. 30, 2025)

Great Novel Therapeutics Biotech & Medicals EV-to-EBIT Chart

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EV-to-EBIT	Get a 7-Day Free Trial							-28.29	-	-34.48	-	-8.70

Competitive Comparison of Great Novel Therapeutics Biotech & Medicals's EV-to-EBIT

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Great Novel Therapeutics Biotech & Medicals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's EV-to-EBIT falls into.

Great Novel Therapeutics Biotech & Medicals EV-to-EBIT Calculation

Great Novel Therapeutics Biotech & Medicals's EV-to-EBIT for today is calculated as:

Great Novel Therapeutics Biotech & Medicals's current Enterprise Value is NT$1,123.27 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Great Novel Therapeutics Biotech & Medicals's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-104.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Great Novel Therapeutics Biotech & Medicals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Great Novel Therapeutics Biotech & Medicals's Enterprise Value for the quarter that ended in Dec. 2024 was NT$911.60 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Great Novel Therapeutics Biotech & Medicals's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-104.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Great Novel Therapeutics Biotech & Medicals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Great Novel Therapeutics Biotech & Medicals Business Description